Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CLLS)
NASDAQ:CLLS
Top Page
Cellectis SA
(NASDAQ:CLLS)
46Neutral
Positive Factors
Clinical Programs
Cellectis is making substantial progress across its clinical programs following a pipeline overhaul and strategic investment by AZN.
Financial Performance
Cellectis reported 3Q24 revenue of $18.1M versus an estimate of $11.2M.
Strategic Partnerships
The AstraZeneca research partnership is off to a strong start with three programs underway and meaningful revenues triggered to date.
Negative Factors
Project Prioritization
UCART123 (AMELI-01 trial) is deprioritized.
Resource Allocation
Cellectis management has decided to focus their resources on the UCART22 and UCART20x22 programs, and are deprioritizing the development of UCART123 in AML.
Cellectis SA (CLLS) vs. S&P 500 (SPY)
Market Cap
$97.65M
Dividend YieldN/A
Average Volume (3M)593.29K
Price to Earnings (P/E)―
Beta (1Y)4.28
Revenue Growth5397.35%
EPS Growth77.93%
CountryUS
Employees221
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.37
Shares Outstanding72,093,636
10 Day Avg. Volume1,572,838
30 Day Avg. Volume593,294
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.92
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.50Price Target Upside323.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cellectis SA Business Overview & Revenue Model
Company DescriptionCellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
How the Company Makes MoneyCellectis makes money primarily through strategic partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and potential royalties based on the successful development and commercialization of products stemming from its gene-editing technologies. Additionally, Cellectis may generate revenue by advancing its own proprietary pipeline of CAR-T cell therapies through clinical trials, with the potential of achieving regulatory approvals and subsequent commercialization. The company's business model leverages its intellectual property and technological expertise in gene editing to create value and establish revenue streams from both collaborative and independent development efforts.
Cellectis SA Financial Statement Overview
Summary
Overall, Cellectis SA's financial statements reflect a company facing profitability challenges but showing some improvement in cash management. The balance sheet remains stable with moderate leverage, though profitability metrics need substantial improvement to ensure long-term viability.Income Statement
The income statement reveals significant challenges in profitability, with a consistent negative net income and deteriorating EBIT and EBITDA margins over time. Although there was a notable increase in revenue TTM, margins remain negative, reflecting ongoing operational challenges.35
Negative
Balance Sheet
The balance sheet shows a moderate debt-to-equity ratio, indicating a manageable level of leverage. However, the equity ratio is declining, which suggests increasing liabilities relative to assets. The negative net income impacts the return on equity adversely.50
Neutral
Cash Flow
Cash flow analysis highlights improvement in free cash flow TTM, driven by better operating cash flow. The operating cash flow to net income ratio suggests operational cash generation is improving compared to the net losses, indicating better cash management.60
Neutral
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 29.07M | 755.00K | 19.17M | 73.95M | 73.95M | 15.19M | Gross Profit |
| 9.71M | 18.00K | 17.40M | 37.67M | 37.67M | 3.80M | EBIT |
| -90.43M | -106.63M | -89.67M | -85.44M | -85.44M | -123.55M | EBITDA |
| -70.19M | -92.64M | -76.38M | -86.46M | -34.68M | -105.09M | Net Income Common Stockholders |
| -85.55M | -101.06M | -98.69M | -86.28M | -72.57M | -90.69M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 451.89M | 203.81M | 97.70M | 186.13M | 268.24M | 360.91M | Total Assets |
| 500.84M | 334.27M | 261.22M | 382.08M | 469.47M | 467.47M | Total Debt |
| 1.35M | 92.85M | 82.85M | 102.24M | 111.30M | 47.61M | Net Debt |
| -450.54M | -43.85M | -14.85M | -83.90M | -156.94M | -313.30M | Total Liabilities |
| 50.57M | 249.57M | 135.28M | 145.60M | 160.63M | 112.00M | Stockholders Equity |
| 409.30M | 84.69M | 117.97M | 221.29M | 275.57M | 315.12M |
| Cash Flow | Free Cash Flow | ||||
| 59.92M | -25.82M | -89.89M | -124.31M | -126.52M | -82.10M | Operating Cash Flow |
| 62.26M | -24.75M | -87.44M | -104.56M | -80.26M | -69.14M | Investing Cash Flow |
| -99.80M | -15.51M | -2.76M | 7.28M | -54.34M | -35.87M | Financing Cash Flow |
| 128.26M | 82.86M | 1.15M | 47.52M | 27.32M | -3.86M |
Cellectis SA Technical Analysis
Neutral
1.30
Price Trends
1.47
Negative
1.66
Negative
1.90
Negative
Market Momentum
-0.06
Negative
44.91
Neutral
58.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLLS, the sentiment is Neutral. The current price of 1.3 is above the 20-day moving average (MA) of 1.29, below the 50-day MA of 1.47, and below the 200-day MA of 1.90, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 44.91 is Neutral, neither overbought nor oversold. The STOCH value of 58.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLLS.
Cellectis SA Risk Analysis
Cellectis SA disclosed 102 risk factors in its most recent earnings report. Cellectis SA reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cellectis SA Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | $6.95B | 0.65 | -53.57% | 2.47% | 21.51% | 0.74% | |
46 Neutral | $97.65M | ― | -34.08% | ― | 5397.35% | 77.93% | |
46 Neutral | $3.53B | ― | -19.20% | ― | -89.95% | -123.71% | |
42 Neutral | $38.57M | ― | -270.20% | ― | 144.50% | -141.91% | |
41 Neutral | $188.55M | ― | -187.83% | ― | -67.20% | 64.66% | |
39 Underperform | $113.68M | ― | -98.10% | ― | -58.64% | -40.05% | |
39 Underperform | $900.60M | ― | -54.00% | ― | 59.55% | 3.09% |
* Healthcare Sector Average
Performance Comparison
CLLS
Cellectis SA
1.30
-1.28
-49.61%
SGMO
Sangamo Biosciences
0.87
0.23
35.94%
BLUE
Bluebird Bio
3.90
-23.30
-85.66%
EDIT
Editas Medicine
1.31
-6.05
-82.20%
NTLA
Intellia Therapeutics
9.00
-17.83
-66.46%
CRSP
Crispr Therapeutics AG
41.22
-29.86
-42.01%
Cellectis SA Earnings Call Summary
Earnings Call Date: Mar 13, 2025 | % Change Since: 0.78% | Next Earnings Date: May 7, 2025
Earnings Call Sentiment Positive
The earnings call reflected a positive outlook for Cellectis, highlighted by strategic collaborations, strong financial positioning, and advancements in clinical trials. Challenges include ongoing arbitration with Servier and patient enrollment progress, but these are outweighed by the company's achievements.Highlights
Strategic Collaboration with AstraZeneca
Cellectis announced the start of three research and development programs under its collaboration with AstraZeneca, including allogeneic CAR T for hematological malignancies, solid tumors, and an in vivo gene therapy for a genetic disorder. AstraZeneca also completed an additional equity investment of $140 million in Cellectis.
Financial Stability and Cash Runway
Cellectis drew down the last tranches of a €40 million credit facility with the European Investment Bank and reported that their cash runway allows operations to be funded into mid-2027. As of December 31, 2024, the company had $264 million in cash, cash equivalents, and fixed term deposits, up from $156 million the previous year.
FDA and European Commission Designations
The FDA granted Orphan Drug Designation and Rare Pediatric Disease status to UCART22, and the European Commission granted Orphan Drug Designation for the treatment of relapse or refractory acute lymphoblastic leukemia.
Advancements in Clinical Trials
Cellectis expects to present Phase 1 data for UCART22 and UCART20x22 in 2025, with plans to open Phase 2 studies in Q4 2025. Recruitment for the BALLI-01 study evaluating UCART22 has progressed well.
Positive Financial Performance
Thanks to the AstraZeneca collaboration, $47 million were received up to year-end 2024, including $22 million from development milestones.
Promising Innovation in CAR T Strategies
Cellectis showcased promising CAR T strategies utilizing TALEN gene editing technology, with preclinical data presented at major conferences and publications in scientific journals.
Lowlights
Servier Arbitration
There is ongoing arbitration with Servier, although specific details remain undisclosed.
Challenges in Patient Enrollment
Enrollment for the NATHALI-01 study of UCART20x22 in relapsed or refractory non-Hodgkin's lymphoma continues, but specific challenges or delays in enrollment were not detailed.
Company Guidance
In the recent Cellectis earnings call for fiscal year 2024, the company provided guidance on several key metrics. Cellectis announced that its cash runway is now extended to mid-2027, thanks to an additional equity investment of $140 million from AstraZeneca, which now owns approximately 44% of Cellectis' share capital and 30% of voting rights. The company also reported that it received $47 million under its collaboration with AstraZeneca, including $25 million upfront and $22 million from development milestones. Cellectis' cash, cash equivalents, and financial assets increased to $264 million as of December 31, 2024, compared to $156 million in the previous year. This increase is attributed to the equity investment, $20 million from the European Investment Bank credit facility, and revenue from partnerships, offset by operational expenses. The company expects to present Phase 1 data for UCART22 and UCART20x22 in 2025 and continues to advance its core clinical trials and collaboration with AstraZeneca.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.